Amend Surgical

Executive Summary

Amend Surgical is a privately-held medical device company advancing a platform of bio-inspired adhesive and barrier technologies for challenging surgical and dental environments. The company's lead products, Amend Tissue Tape and Tissure, aim to replace short-acting glues and sutures in oral wound care and nerve repair, addressing significant unmet needs for long-lasting, biocompatible solutions. Additionally, Amend's commercial product, NanoFUSE, combines bioactive glass and demineralized bone allograft for orthopedic and spinal fusion, providing an innovative alternative in the growing spine market. Founded in 2015 and headquartered in Atlanta, Georgia, the company is positioned to capitalize on the convergence of regenerative medicine and advanced materials. Amend Surgical's strategy focuses on leveraging its proprietary technology platform to expand into multiple surgical indications. The recent approval of NanoFUSE provides a revenue-generating foundation while the earlier-stage tissue adhesive products target larger opportunities in wound closure and nerve repair. The company's progress in clinical validation and regulatory submissions will be key to unlocking value. With a strong IP portfolio and a clear clinical need for improved surgical adhesives, Amend Surgical is well-poised for growth. However, as a private entity, it faces execution risks and capital requirements typical of the medical device sector.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or CE mark for Amend Tissue Tape70% success
• Q1 2027Publication of pivotal clinical trial results for Tissure nerve repair60% success
• Q2 2026Series B or strategic partnership announcement to fund commercial expansion50% success